Researchers have developed the world’s first real-world head-to-head testing platform to determine whether commercial artificial intelligence (AI) algorithms are fit for NHS use to detect disease in a fair, equitable, transparent and trustworthy way, using diabetic eye disease as the first example. They say that it removes any biases that can come from companies wanting to deploy their AI software in clinical settings, putting all companies on a level playing field.